[go: up one dir, main page]

WO2002026718A3 - Bicyclic pyrimidin-4-one based inhibitors of factor xa - Google Patents

Bicyclic pyrimidin-4-one based inhibitors of factor xa Download PDF

Info

Publication number
WO2002026718A3
WO2002026718A3 PCT/US2001/030335 US0130335W WO0226718A3 WO 2002026718 A3 WO2002026718 A3 WO 2002026718A3 US 0130335 W US0130335 W US 0130335W WO 0226718 A3 WO0226718 A3 WO 0226718A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
compounds
based inhibitors
bicyclic pyrimidin
pyrimidin
Prior art date
Application number
PCT/US2001/030335
Other languages
French (fr)
Other versions
WO2002026718A2 (en
Inventor
Penglie Zhang
Wenhao Li
Wenrong Huang
Lingyan Wang
Zhaozhong Jon Jia
Robert M Scarborough
Bing-Yan Zhu
Original Assignee
Millennium Pharm Inc
Penglie Zhang
Wenhao Li
Wenrong Huang
Lingyan Wang
Zhaozhong Jon Jia
Robert M Scarborough
Bing-Yan Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Penglie Zhang, Wenhao Li, Wenrong Huang, Lingyan Wang, Zhaozhong Jon Jia, Robert M Scarborough, Bing-Yan Zhu filed Critical Millennium Pharm Inc
Priority to AU2002214546A priority Critical patent/AU2002214546A1/en
Publication of WO2002026718A2 publication Critical patent/WO2002026718A2/en
Publication of WO2002026718A3 publication Critical patent/WO2002026718A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Novel bicyclic pyrimidin-4-one-containing compounds of formulae (I) or (II): including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and the compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
PCT/US2001/030335 2000-09-29 2001-10-01 Bicyclic pyrimidin-4-one based inhibitors of factor xa WO2002026718A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002214546A AU2002214546A1 (en) 2000-09-29 2001-10-01 Bicyclic pyrimidin-4-one based inhibitors of factor xa

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23633100P 2000-09-29 2000-09-29
US60/236,331 2000-09-29

Publications (2)

Publication Number Publication Date
WO2002026718A2 WO2002026718A2 (en) 2002-04-04
WO2002026718A3 true WO2002026718A3 (en) 2002-08-29

Family

ID=22889064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030335 WO2002026718A2 (en) 2000-09-29 2001-10-01 Bicyclic pyrimidin-4-one based inhibitors of factor xa

Country Status (2)

Country Link
AU (1) AU2002214546A1 (en)
WO (1) WO2002026718A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524957B2 (en) 2001-08-17 2009-04-28 Astrazeneca Ab Compounds effecting glucokinase
US7642263B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1553947A4 (en) * 2002-10-21 2006-11-29 Bristol Myers Squibb Co Quinazolinones and derivatives thereof as factor xa inhibitors
AR051596A1 (en) * 2004-10-26 2007-01-24 Irm Llc CONDENSED HETEROCICLIC COMPOUNDS NITROGENATED AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF FOOD DISORDERS
US20090163521A1 (en) * 2005-06-28 2009-06-25 Orchid Research Laboratories Limited Novel Pyrazolopyrimidinone Derivatives
US8003656B2 (en) 2006-08-23 2011-08-23 Neurogen Corporation 2-phenoxy pyrimidinone analogues
JP5635535B2 (en) * 2009-01-08 2014-12-03 レスバーロジックス コーポレイション Compounds for the prevention and treatment of cardiovascular disease
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
BR112017000043A2 (en) * 2014-07-03 2018-07-17 Celgene Quanticel Research, Inc. lysine-1 specific demethylase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276295A (en) * 1978-12-19 1981-06-30 Masayuki Ishikawa 3-Aromatic moiety substituted-4(3H)-quinazolinones, process for production thereof, and use thereof
WO1999054313A1 (en) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Bicyclic compounds having an anti-thrombitic effect

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276295A (en) * 1978-12-19 1981-06-30 Masayuki Ishikawa 3-Aromatic moiety substituted-4(3H)-quinazolinones, process for production thereof, and use thereof
WO1999054313A1 (en) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Bicyclic compounds having an anti-thrombitic effect

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524957B2 (en) 2001-08-17 2009-04-28 Astrazeneca Ab Compounds effecting glucokinase
US7642263B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes

Also Published As

Publication number Publication date
WO2002026718A2 (en) 2002-04-04
AU2002214546A1 (en) 2002-04-08

Similar Documents

Publication Publication Date Title
WO2001056989A3 (en) Inhibitors of factor xa
WO2001064643A3 (en) Benzamides and related inhibitors of factor xa
WO2002026712A3 (en) Quaternary amines and related inhibitors of factor xa
WO2001072708A3 (en) OXINDOLE INHIBITORS OF FACTOR Xa
WO2001057021A3 (en) 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
WO2000071507A3 (en) INHIBITORS OF FACTOR Xa
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
IL183340A0 (en) [1,2,4] triazolo[4,3-a] pyridine derivatives and pharmaceutical compositions containing them
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
AU5879299A (en) Adenine derivatives
WO2002026720A3 (en) PIPERAZINE BASED INHIBITORS OF FACTOR Xa
AU2002246728A1 (en) Carboline derivatives
HK1089163A1 (en) Quinoxaline derivatives as neutrophil elastase inhibitors and their use
WO2000071515A3 (en) INHIBITORS OF FACTOR Xa
DK1029853T3 (en) Heteroaromatic bicyclic derivatives useful as anticancer agents
ZA200306419B (en) Phenyl derivatives.
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
AU2003228674A1 (en) Muscarinic antagonists
AU2002249890A1 (en) Carboline derivatives
AU2002213421A1 (en) Condensed pyridoindole derivatives
WO2002026718A3 (en) Bicyclic pyrimidin-4-one based inhibitors of factor xa
WO1996040743A3 (en) Inhibitors of factor xa
WO2002026731A3 (en) Quaternary amidino based inhibitors of factor xa
EA200201149A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE PREVENTION OF THE RECURRENCE OF MIGRAINE
NO983444L (en) Benzo (c) quinolizine derivatives, their preparation and use as 5 <alfa> reductase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP